Sign in

    Edward Marks

    Research Analyst at Needham & Company

    Edward Marks is an Equity Research Biopharmaceuticals Associate at Needham & Company, specializing in equity research within the biopharmaceutical sector. He covers a range of biopharmaceutical companies, contributing research and analysis that supports investment decisions, although specific performance metrics such as success rates or rankings on platforms like TipRanks have not been publicly disclosed. Marks began his career as an Equity Research Associate at Ladenburg Thalmann & Co., Inc., followed by a similar role at H.C. Wainwright before joining Needham & Company, underscoring his deep experience in healthcare equity research. While detailed credentials and FINRA registrations are not confirmed from available sources, his current and prior roles indicate a strong background in equity research and financial analysis within the biopharmaceutical industry.

    Edward Marks's questions to Stoke Therapeutics (STOK) leadership

    Edward Marks's questions to Stoke Therapeutics (STOK) leadership • Q2 2025

    Question

    Edward Marks, on behalf of Joseph Stringer from Needham & Company, asked about the timing of the North American commercial build-out and sales force size, as well as details on the ADOA Phase 1 trial, including genetic screening requirements and data cadence.

    Answer

    Chief Patient Officer Jason Hoitt outlined a slow, deliberate commercial build, anticipating a peak of around 20 salespeople with a focus on patient support. Interim CEO Ian Smith added the strategy is centered on education and access, not a traditional sales model. For ADOA, he described the Phase 1 as a safety-focused, dose-escalating study where updates will be provided if meaningful efficacy data emerges. CMO Barry Ticho noted that OPA1 genetic testing is available but underutilized, necessitating an education campaign.

    Ask Fintool Equity Research AI

    Edward Marks's questions to Cidara Therapeutics (CDTX) leadership

    Edward Marks's questions to Cidara Therapeutics (CDTX) leadership • Q2 2025

    Question

    Edward Marks, on for Joey Stringer, asked about the assumptions built into the company's cash runway guidance, including funding for a redosing trial, and for the potential commercial read-through for CD388 from Sanofi's guided decline in its flu business.

    Answer

    CFO Frank Karbe stated that the company's cash on hand is sufficient to fund operations through the completion of the Phase 3 program, including additional studies and various potential scenarios. Chief Business Officer Jim Beitel added that downward pressure on traditional vaccine businesses is largely unrelated to CD388's strategy, which focuses on high-risk populations with a unique value proposition and a different commercial model.

    Ask Fintool Equity Research AI

    Edward Marks's questions to Savara (SVRA) leadership

    Edward Marks's questions to Savara (SVRA) leadership • Q1 2020

    Question

    Edward Marks of Ladenburg Thalmann inquired about the expected timeline for FDA discussions regarding the NCFB program and asked for details on any design changes for the IMPALA 2 trial compared to the original IMPALA study.

    Answer

    COO Taneli Jouhikainen stated that FDA discussions for the NCFB program are a priority for the current year but could not provide a specific timeline for outcomes. Chief Medical Officer Badrul Chowdhury detailed the key differences in the IMPALA 2 trial design, which include dropping the intermittent dosing arm, changing the primary endpoint to DLCO (diffusing capacity for carbon monoxide), and extending the placebo-controlled treatment period from six months to 48 weeks.

    Ask Fintool Equity Research AI